308 related articles for article (PubMed ID: 24845948)
1. Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia.
Mattioni S; Pavie J; Porcher R; Scieux C; Denis B; De Castro N; Simon F; Molina JM
Int J STD AIDS; 2015 Apr; 26(5):306-12. PubMed ID: 24845948
[TBL] [Abstract][Full Text] [Related]
2. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.
Wohl DA; Kendall MA; Andersen J; Crumpacker C; Spector SA; Feinberg J; Alston-Smith B; Owens S; Chafey S; Marco M; Maxwell S; Lurain N; Jabs D; Benson C; Keiser P; Jacobson MA;
HIV Clin Trials; 2009; 10(3):143-52. PubMed ID: 19632953
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).
Erice A; Tierney C; Hirsch M; Caliendo AM; Weinberg A; Kendall MA; Polsky B;
Clin Infect Dis; 2003 Aug; 37(4):567-78. PubMed ID: 12905142
[TBL] [Abstract][Full Text] [Related]
4. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.
Grzywacz M; Deayton JR; Bowen EF; Wilson P; Emery VC; Johnson MA; Griffiths PD
J Med Virol; 1999 Nov; 59(3):323-8. PubMed ID: 10502264
[TBL] [Abstract][Full Text] [Related]
5. The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment.
Bigliano P; Calcagno A; Lucchini A; Audagnotto S; Montrucchio C; Marinaro L; Alcantarini C; Ghisetti V; Di Perri G; Bonora S
Antivir Ther; 2018; 23(5):451-456. PubMed ID: 29372886
[TBL] [Abstract][Full Text] [Related]
6. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality.
Durier N; Ananworanich J; Apornpong T; Ubolyam S; Kerr SJ; Mahanontharit A; Ferradini L; Ruxrungtham K; Avihingsanon A
Clin Infect Dis; 2013 Jul; 57(1):147-55. PubMed ID: 23511301
[TBL] [Abstract][Full Text] [Related]
8. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
9. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Chakrabarti S; Collingham KE; Osman H; Fegan CD; Milligan DW
Bone Marrow Transplant; 2001 Nov; 28(9):879-81. PubMed ID: 11781649
[TBL] [Abstract][Full Text] [Related]
10. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
[TBL] [Abstract][Full Text] [Related]
12. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.
Chawla JS; Ghobadi A; Mosley J; Verkruyse L; Trinkaus K; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Uy GL; Westervelt P; DiPersio JF; Vij R
Transpl Infect Dis; 2012 Jun; 14(3):259-67. PubMed ID: 22093134
[TBL] [Abstract][Full Text] [Related]
13. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation.
Aigner C; Jaksch P; Winkler G; Czebe K; Taghavi S; Marta G; Klepetko W
Wien Klin Wochenschr; 2005 Jul; 117(13-14):480-4. PubMed ID: 16091875
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus viraemia in HIV exposed and infected infants: prevalence and clinical utility for diagnosing CMV pneumonia.
Hsiao NY; Zampoli M; Morrow B; Zar HJ; Hardie D
J Clin Virol; 2013 Sep; 58(1):74-8. PubMed ID: 23727304
[TBL] [Abstract][Full Text] [Related]
15. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
[TBL] [Abstract][Full Text] [Related]
16. Impact of highly active antiretroviral therapy on cytomegalovirus viraemia in the absence of specific anti-cytomegalovirus therapy.
Mihăilescu R; Arama V; Paraschiv S; Streinu-Cercel A; Oţelea D; Munteanu D; Iosipenco M; Chiotan C; Benea OE; Mărdărescu M; Rădulescu M; Hristea A; Ungurianu R; Aramă SS; Cercel AS; Călin R; Băicuş C
Rom J Intern Med; 2008; 46(4):305-11. PubMed ID: 19480296
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of the plasma load of cytomegalovirus in patients infected with HIV--a survival analysis.
Aramă V; Mihăilescu R; Rădulescu M; Aramă SŞ; Streinu-Cercel A; Youle M;
J Med Virol; 2014 Nov; 86(11):1821-7. PubMed ID: 25087866
[TBL] [Abstract][Full Text] [Related]
18. Low frequency of cytomegalovirus (CMV) disease despite high prevalence of CMV viraemia in patients with advanced HIV infection: a clinical and immunological 48-week follow-up study.
Albasanz-Puig A; Suanzes P; Esperalba J; Fernández C; Sellarès-Nadal J; Torrella A; Planas B; Segura A; Burgos J; Ribera E; Cañas-Ruano E; García JN; Navarro J; Curran A; Len Ó; Falcó V
HIV Med; 2021 Sep; 22(8):682-689. PubMed ID: 33998115
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
[TBL] [Abstract][Full Text] [Related]
20. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.
Owers DS; Webster AC; Strippoli GF; Kable K; Hodson EM
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD005133. PubMed ID: 23450558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]